New data presented at ats 2024 show the potential of tezspire to play a role in the future treatment of chronic obstructive pulmonary disease

Wilmington, del.--(business wire)--the phase iia course trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (copd) with a broad range of blood eosinophil counts (bec) and irrespective of emphysema, chronic bronchitis or smoking status.1 the primary results showed that treatment with astrazeneca and amgen's tezspire® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe copd exacerbations compared to pl.
ATS Ratings Summary
ATS Quant Ranking